- Home
- GXAI vs SLXN Comparison
GXAI vs SLXN Comparison
Compare GXAI & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- SLXN
- Stock Information
- Founded
- GXAI 2021
- SLXN 2008
- Country
- GXAI United States
- SLXN Israel
- Employees
- GXAI N/A
- SLXN N/A
- Industry
- GXAI
- SLXN
- Sector
- GXAI
- SLXN
- Exchange
- GXAI Nasdaq
- SLXN NYSE
- Market Cap
- GXAI 2.5M
- SLXN 3.0M
- IPO Year
- GXAI 2023
- SLXN N/A
- Fundamental
- Price
- GXAI $1.41
- SLXN $0.21
- Analyst Decision
- GXAI
- SLXN Strong Buy
- Analyst Count
- GXAI 0
- SLXN 1
- Target Price
- GXAI N/A
- SLXN $1.00
- AVG Volume (30 Days)
- GXAI 3.7M
- SLXN 1.5M
- Earning Date
- GXAI 11-26-2024
- SLXN 11-14-2024
- Dividend Yield
- GXAI N/A
- SLXN N/A
- EPS Growth
- GXAI N/A
- SLXN N/A
- EPS
- GXAI N/A
- SLXN N/A
- Revenue
- GXAI $2,979.00
- SLXN N/A
- Revenue This Year
- GXAI N/A
- SLXN N/A
- Revenue Next Year
- GXAI N/A
- SLXN N/A
- P/E Ratio
- GXAI N/A
- SLXN N/A
- Revenue Growth
- GXAI N/A
- SLXN N/A
- 52 Week Low
- GXAI $1.25
- SLXN $0.21
- 52 Week High
- GXAI $19.20
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- GXAI 46.13
- SLXN N/A
- Support Level
- GXAI $1.37
- SLXN N/A
- Resistance Level
- GXAI $2.49
- SLXN N/A
- Average True Range (ATR)
- GXAI 0.15
- SLXN 0.00
- MACD
- GXAI 0.03
- SLXN 0.00
- Stochastic Oscillator
- GXAI 6.90
- SLXN 0.00
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.